Testing a new immune cell therapy for children with blood cancers

This trial is testing a new treatment called Obecabtagene Autoleucel (obe-cel) for children under 18 who have blood cancers that have come back or stopped responding to other treatments. The medication works by taking immune cells from your body, training them in the laboratory to recognize and fight cancer cells, and then putting them back into your body. Researchers want to see if this approach is safe and effective for children with these difficult-to-treat cancers.

Children with relapsed or refractory blood cancers often have few treatment options left, and the cancers can be life-threatening. This trial exists to see if this new medication—which harnesses the body's own immune system—can help children whose cancers have stopped responding to standard treatments.